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Abstract
Background: Despite strong evidence for the effectiveness of anti-retroviral therapy for improving the health of women
living with HIV and for the prevention of mother-to-child transmission (PMTCT), HIV persists as a major maternal and child
health problem in sub-Saharan Africa. In most settings antenatal care (ANC) services and HIV treatment services are offered
in separate clinics. Integrating these services may result in better uptake of services, reduction of the time to treatment
initiation, better adherence, and reduction of stigma.
Methodology/Principal Findings: A prospective cluster randomized controlled trial design was used to evaluate the effects
of integrating HIV treatment into ANC clinics at government health facilities in rural Kenya. Twelve facilities were
randomized to provide either fully integrated services (ANC, PMTCT, and HIV treatment services all delivered in the ANC
clinic) or non-integrated services (ANC clinics provided ANC and basic PMTCT services and referred clients to a separate HIV
clinic for HIV treatment). During June 2009– March 2011, 1,172 HIV-positive pregnant women were enrolled in the study.
The main study outcomes are rates of maternal enrollment in HIV care and treatment, infant HIV testing uptake, and HIV-
free infant survival. Baseline results revealed that the intervention and control cohorts were similar with respect to socio-
demographics, male partner HIV testing, sero-discordance of the couple, obstetric history, baseline CD4 count, and WHO
Stage. Challenges faced while conducting this trial at low-resource rural health facilities included frequent staff turnover,
stock-outs of essential supplies, transportation challenges, and changes in national guidelines.
Conclusions/Significance: This is the first randomized trial of ANC and HIV service integration to be conducted in rural
Africa. It is expected that the study will provide critical evidence regarding the implementation and effectiveness of this
service delivery strategy, with important implications for programs striving to eliminate vertical transmission of HIV and
improve maternal health.
Trial Registration: ClinicalTrials.gov NCT00931216 http://clinicaltrials.gov/ct2/show/NCT00931216.
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Introduction
Despite the strong evidence for the effectiveness of anti-
retroviral (ARV) drugs for improving the health of HIV-infected
women and for the prevention of mother-to-child transmission
(PMTCT) [1,2], HIV-related morbidity and mortality among
childbearing women and vertical transmission of HIV from
mother to child continue to be major health problems in sub-
Saharan Africa [3,4]. In order to improve health outcomes,
women need to successfully navigate a cascade of services
including antenatal care (ANC) clinic attendance, acceptance of
HIV testing, receipt of results, enrollment in HIV care, acceptance
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of ARV prophylaxis or treatment, adherence with maternal
antiretroviral (ARV) prophylaxis or treatment, adherence to infant
ARV prophylactic doses, and early infant HIV testing [5].
Unfortunately, a significant proportion of women and their infants
drop out at each step along this cascade thus decreasing the
effectiveness of PMTCT programs [6–9]. The 2009 Expert
Consultation on Implementation Science Research sponsored by
the NIH Office of AIDS Research identified as a top priority
research on how to promote women’s linkage to and retention in
care at each step of this PMTCT cascade [10].
One promising approach for improving linkages to and
retention in services for women and infants is to fully integrate
HIV care into ANC clinics [11]. Although definitions of
‘‘integration’’ vary, experiences in sub-Saharan Africa suggest
that integrating ANC and HIV services may result in a variety of
benefits for HIV-positive women and their families; including
better uptake of services, more women receiving counselling,
reduction of the time to treatment initiation, improved quality of
care, and reduction of stigma [12–17]. Lack of integration of
PMTCT into routine maternal and child health services has been
identified as one of the major contributors to drop-off of women
and infants at various steps in the PMTCT cascade [18]. On the
other hand, the potential downsides of integration in low-resource
settings include: increased provider workload in an already
overburdened system, increased training needs, lack of space
and equipment, lack of staff motivation to provide more services,
and even ‘‘organizational culture clash’’ [19–21]. From the
perspective of clients, it is possible that integration of HIV services
into ANC clinics could have negative effects–such as increased
wait times–for the majority of clients who are HIV-negative [22].
Since 92% of women in Kenya have at least one antenatal care
visit during pregnancy, ANC clinics have become prime locations
for expansion of HIV testing and PMTCT services in this country
[23]. Due to these efforts, rates of antenatal HIV testing have been
increasing over time in Kenya – approximately 73% of pregnant
women were tested during 2008–2009 [23]; however, only an
estimated 72% of pregnant women who tested HIV-positive
received antiretroviral medications for PMTCT in 2009 [24].
Antenatal care has been modified to include PMTCT services, but
generally has not included comprehensive HIV care and treatment
for pregnant women. Comprehensive HIV care and treatment
encompasses the clinical and social components necessary for the
highest quality of care, including opportunistic infection prophy-
laxis, tuberculosis (TB) diagnosis and treatment, WHO clinical
staging for HIV, highly active antiretroviral therapy (HAART),
CD4 count monitoring, relevant laboratory tests (such as complete
blood counts, creatinine, liver enzymes, etc.), adherence counsel-
ing, peer education, and access to support groups. In most ANC
clinics in Kenya, HIV-positive pregnant women are normally
referred to a separate HIV clinic for care and treatment (either
located elsewhere on the grounds of the health facility or at
another health facility), which may operate at different times and
days than the ANC clinic.
As elsewhere, the Kenyan national guidelines for PMTCT–
including recommendations for infant feeding, CD4 count
monitoring, and HAART initiation–have been evolving over
time. In August 2010 the Kenyan PMTCT guidelines were
updated [25]. These guidelines recommended earlier initiation of
HAART for a larger group of HIV-positive pregnant women
(WHO clinical stage III or IV regardless of CD4 count OR WHO
clinical stage I or II with CD4 count ,350/mm3, compared with
previous recommendations of WHO clinical stage of III or IV OR
CD4 count ,200/mm3) to benefit both the health of the mother
and prevent HIV transmission to her child during pregnancy and
breastfeeding. The ARV prophylaxis regimen guidelines were also
changed in 2010, to start at 14 weeks or at first contact thereafter,
compared with previous guidelines that recommended initiating
prophylaxis at 28 weeks. The new PMTCT guidelines also include
provision of ARV prophylaxis (zidovudine and lamivudine) to the
mother for 7 days after the delivery and daily infant prophylaxis
with nevirapine (NVP) monotherapy until one week after
breastfeeding cessation if mother is not on HAART or up to 6
weeks of age if mother is on HAART.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement
This study was approved by the Committee on Human
Research of the University of California, San Francisco
(FWA00000068) and the Ethical Review Committee of the Kenya
Medical Research Institute (FWA00002066). The study protocol
was also approved by the Associate Director for Science at the US
Centers for Disease Control and Prevention. All women partic-
ipating in the study gave written informed consent for the use of
their de-identified data in the evaluation. Participation in the study
did not require additional research activities beyond women’s
regular antenatal and HIV care. This clinical trial is registered at
clinicaltrials.gov NCT00931216.
Objectives
The primary aim of the Study of HIV and Antenatal care
Integration in Pregnancy (SHAIP) is to test if an integrated
approach to ANC, PMTCT, and HIV care and treatment
provision is an effective service model for low-resource health
facilities in rural Nyanza Province, Kenya, with implications for
other sites in Kenya and sub-Saharan Africa. In this study,
‘‘service integration’’ has been defined as integrating HIV care
and treatment services, including initiation and provision of
HAART for eligible women, into existing ANC and PMTCT
services, with all services provided by the same health care
provider in the same room during ANC visits for the duration of
the pregnancy and until a definitive HIV diagnosis of the child (up
to 18 months), after which point the woman and infant, if HIV-
infected, would be referred to the HIV clinic. Women and infants
who presented for HIV care were enrolled on the same day or at
the subsequent visit.
We hypothesized that the integrated model would lead to
increased uptake of HIV care and treatment for women and
infants and thus improved maternal health outcomes and reduced
vertical transmission of HIV, as compared to a non-integrated
model. While experience and related studies have indicated that
integration of services may improve uptake and utilization of HIV
care and treatment by pregnant women, full integration needs
rigorous evaluation before adoption on a wider scale [12,20,26–
29]. Thus, in order to ensure provision of the highest quality ANC,
PMTCT, and comprehensive HIV care and treatment to
pregnant women, a new service model should have strong
evidence supporting its effectiveness.
The Setting
In March 2005, the Kenya Medical Research Institute
(KEMRI) and University of California, San Francisco (UCSF),
supported by the President’s Emergency Plan for AIDS Relief
(PEPFAR)/Centers for Disease Control (CDC), launched Family
Study of HIV and Antenatal Care Integration
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AIDS Care and Education Services (FACES) in Nairobi and
Kisumu, Kenya [30]. As one of the PEPFAR local partners in
Kenya, FACES works to support the Kenyan Ministries of Health
(MoH) in the implementation of quality HIV services including
PMTCT at existing public and private health facilities; by
providing training, clinical mentorship, logistical support, com-
munity engagement activities; as well as employing lay health
workers based at peripheral sites and provision of salary support
for MoH health workers. FACES currently supports 123 PMTCT
sites in Nyanza Province.
As of 2008, HIV prevalence in Nyanza Province was estimated
at 16.0% of reproductive-aged women, which is the highest HIV
prevalence in the country and more than double the national
average [23]. The study sites are located in the southern part of
Nyanza Province, bordering Tanzania to the south and covering a
third of Kenya’s shoreline of Lake Victoria. The main economic
activities in this area are fishing and farming.
Study Design
SHAIP is a prospective cluster randomized trial. This design
was chosen because service integration is an intervention that is
carried out on a clinic-level, rather than at an individual patient
level; it would be practically impossible to randomize individual
women at a given clinic to receive either fully integrated (FI) or
non-integrated (NI) services. Outcomes for women and infants
attending FI clinics will be compared to those of women and
infants at NI clinics covering the time period from June 2009 -
March 2012. Although clients and providers could not be blinded
as to the type of services delivered, study investigators are blinded
in terms of knowledge of any outcomes by study arm until locking
of the study database.
Randomization
Prior to study initiation, potential sites (government health
facilities in the study area) were assessed to determine the size of
the facility, staffing, patient load, and available services. Inclusion
criteria for sites included the following: 1) providing ANC services,
2) providing HIV testing and ARV services for pregnant women,
and 3) an average of at least 20 new ANC clients per month. Study
sites included all the government health facilities that met these
criteria and were also either providing or scheduled to begin
providing HAART services in these districts by June 2007
(excluding Migori District Hospital, which was much larger in
terms of staffing and patient volume, and thus very different from
other health facilities in the districts, and would have created
imbalance in the study arms) (See Table 1). Twelve facilities were
categorized by facility type, as either ‘‘Health Center or
Dispensary’’ (N= 8) or ‘‘Hospital’’ (N= 4). Within these strata,
each clinic represented a cluster, and was randomized to either
control (NI) or intervention (FI) using the ACluster software [31].
Prior to beginning study enrollment, each site had to have begun
providing comprehensive HIV care and treatment services
including HAART; site staff had to have completed the study
training program, including research ethics; and a site initiation
visit had to have been completed by the external monitor. A map
of Greater Migori District, showing the locations of control (NI)
and intervention (FI) sites is presented as Figure 1.
Table 1 also shows baseline measures of the proportions of a)
HIV+ women receiving PMTCT prophylaxis other than
HAART, b) HIV+ women receiving HAART, and c) HIV-
exposed infants receiving prophylaxis, using data from program
PMTCT reporting tools for the study sites during the six months
prior to study initiation in June 2009 (December 2008–May 2009).
These proportions were very similar for FI and NI sites at baseline
before study enrollment began: 87.3% FI vs. 86.0% NI for
PMTCT prophylaxis received; 11.6% FI vs. 12.3% NI for
HAART received; and 95.1% FI vs. 91.1% NI for infant
prophylaxis received. It should be noted that these proportions
are based on monthly data from clinic registers and may not reflect
actual use/adherence.
Participants
The study population included all pregnant HIV-positive
women, 18 years and older who were not currently enrolled in
HIV care and treatment, as well as infants born to the women
enrolled in the study. Eligible women were introduced to the study
at the ANC clinic and if they were interested in participation they
were taken through an informed consent process in a private
location by a trained lay health worker. A total of 1,172 HIV-
positive pregnant women were enrolled in the study during the
period June 2009–March 2011 (See Figure 2). Of a total of 1,200
eligible women who were offered study enrollment, 81 (6.8%)
declined to participate in the study.
Outcome Measures
The main study outcome measures are rates of maternal
enrollment in HIV care and treatment during the 12-month
follow-up period, infant HIV testing uptake by 3 months of age,
and HIV-free infant survival at 6 months of age. Maternal
enrollment in care is assessed by the existence of a completed HIV
care enrollment form for the woman in the FACES electronic
medical record system, and by calculating time from the date of
study enrollment to the date of enrollment in HIV care. Infant
testing uptake by 3 months after the birth is measured using a
combination of medical record data and study tracking tools.
Mothers were encouraged to bring their infants to the clinic for
HIV testing at 6 weeks of age and 6 weeks after the complete
cessation of breastfeeding, and the FACES program attempted
home visits for HIV-exposed infants who were not brought to the
facility for HIV testing by 3–6 months after the birth (see below).
HIV-free survival at around 6 months of age is calculated by
assessing the numbers of infants who were not lost-to-follow-up
and were still alive and had not tested HIV-positive at around 6
months of age, based on data from medical records and home
visits after the birth.
Infant HIV-Polymerase Chain Reaction (PCR) testing was done
on dried blood spots using Roche DNA PCR version 1.5 (Roche
Diagnostic System). Infant samples were collected from skin prick
and coated onto filter paper. The spotted filter papers were
allowed to dry for at least 4 hours at room temperature and placed
in individual zip locked bags containing a silica desiccant. All these
samples were then transported to the KEMRI-CDC HIV-R
laboratory in Kisumu for PCR testing. This laboratory handles all
Infant HIV-PCR tests for Nyanza Province. Specimens for CD4
testing were collected in EDTA whole blood collection tubes.
CD4/CD3 fluorescent labeled monoclonal antibodies (Becton
Dickinson Biosciences) were used to quantify the CD4 absolute
count using BD FACSCountTM. Additional outcomes to be
assessed for HIV-positive women include: receipt of PMTCT
prophylaxis, initiation of HAART (among HAART-eligible
women), time to initiation of HAART, changes in CD4 counts,
and retention in and adherence to HIV care. Samples for CD4
counts are ideally collected at the time of study enrollment and
every six months or more frequently, if clinically indicated.
Changes in women’s CD4 cell counts from baseline (study
enrollment) to approximately 6 months following study enrollment
will be assessed using medical record data. Monthly tracking tools
and electronic patient records are used to collect data on
Study of HIV and Antenatal Care Integration
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enrollment in HIV care, initiation of HAART, retention in care,
and number of missed visits. Additional study outcomes to be
examined for infants include enrollment in HIV care and uptake
of HAART, if HIV-positive.
Sample Size and Power Calculations
From preliminary site assessments of the clinics conducted in
2006, it was estimated that 6,564 new ANC clients would be seen
in a 12-month period at the 12 study sites. It was expected that an
average of 80% of pregnant women would agree to HIV testing.
At the time when the sample size calculations were performed, the
most recent estimate of HIV prevalence among pregnant women
in Nyanza Province was 25% [32]. These assumptions resulted in
estimates of approximately 1,313 women testing HIV-positive with
a previously unknown HIV-serostatus, and 3,938 being HIV-
negative after the first ANC visit. Assuming that 90% of the
women who tested HIV-positive agreed to participate in the study,
we estimated being able to enroll 1,182 HIV-positive pregnant
women in the study over a period of 12 months.
Power calculations were made based on estimated differences
in vertical transmission rates in the two arms of the study,
accounting for stratification, based on prior published transmis-
sion rates using similar antiretroviral protocols in Thailand and
Cote-D’Ivoire for reference [33–35]. With a sample size of 12
clusters, 591 HIV-positive women per study arm, and an
average of 98 HIV-positive women per health facility (average
in the Hospital stratum of 146 women per facility and average
in the HC/Dispensary stratum of 75 women per facility), we
calculated that we would have 80% power to be able to detect
a minimum odds ratio of 2.02 for vertical transmission, if we
assumed a conservative intracluster correlation coefficient (ICC)
of .01. We also calculated our minimum detectable effect size
with a range of ICCs [36] and found that the minimum
detectable odds ratio ranged from 1.81 for a very low ICC of
.005, to 3.75 if the ICC is as high as .05.
With 99% power, this sample size allows us to detect a mean
difference of 50 cells in CD4 counts between groups, using an
estimated standard deviation of 142 cells and an intra-cluster
correlation coefficient of .01.[37–39] Our power will be 90% if the
ICC is .025, and 80% if the ICC is as high as .037. This sample
size also provides us with exceptional power to examine the other
study outcomes including women’s enrollment in HIV care,
pediatric HIV testing uptake, and loss-to-follow for those who
enroll in HIV care.
Description of Procedures
Health care providers at both FI and NI facilities were trained
and supported to provide high quality ANC, PMTCT, and HIV
care and treatment services throughout the duration of the study.
Refresher trainings were provided on a regular basis, and were
quickly organized in response to significant staff turnover at a site
and/or changes to the Kenyan national PMTCT guidelines.
Study-specific training sessions for the FI and NI clinics included
study procedures, correct filling of patient medical record forms,
Figure 1. Map of SHAIP Study Sites. This map of the Greater Migori District shows the location of control (NI, indicated by green stars) and
intervention (FI, indicated by red stars) health facilities.
doi:10.1371/journal.pone.0044181.g001
Study of HIV and Antenatal Care Integration
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clinic flow and logistics for FI or NI services, informed consent
procedures, and participant eligibility criteria. Clinical trainings
covered the components of high quality ANC, PMTCT, and HIV
treatment for pregnant women; early infant diagnosis; and care
and treatment for HIV-exposed infants and HIV-infected
children.
Figure 2. Consort Diagram. The flow diagram of clusters and individuals through the cluster randomized trial. A total of 1,172 HIV-positive
pregnant women were enrolled in the study during the period June 2009–March 2011.
doi:10.1371/journal.pone.0044181.g002
Study of HIV and Antenatal Care Integration
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The package of ANC, PMTCT, and HIV care and treatment
services offered at the sites has followed current Kenyan national
guidelines in both study arms for the duration of the study, with
the only difference in care being the clinic location of HIV care
and treatment services for pregnant and postpartum women (ANC
clinic versus the HIV clinic). At the NI clinics, HIV-positive
women were given ARVs for PMTCT, clinical staging to
determine eligibility was conducted, and a specimen was taken
for a CD4 count. They were also given a referral form to enroll in
the HIV care and treatment clinic. At the FI clinics, HIV positive
women were provided all ANC, PMTCT, and HIV services in the
ANC clinic including HAART for women who were eligible. (See
Figures 3 and 4).
As mentioned previously, over the course of the study, national
guidelines concerning infant feeding, CD4 count monitoring, and
HAART initiation were updated. The sites complied with each set
of changes shortly after the national guidelines on PMTCT were
announced with the exception of daily NVP for the infant, which
was rolled out to the study sites in October 2010. The changes
were implemented at all study sites simultaneously.
Data Collection Methods
Quantitative data on women and infants were collected
prospectively as part of their routine clinic care. FACES uses an
electronic medical record system using the Open Medical Record
System (OpenMRSH) platform. In the study area, paper medical
record forms were filled out by clinical staff at the health facilities.
Data clerks entered these forms into laptop computers on a regular
basis, and subsequently these data were merged with the larger
FACES database. This dataset includes detailed information on
socio-demographics, health indicators (CD4 counts, WHO Stag-
ing, vertical transmission, etc.) and use of specific HIV and
maternity services by HIV-positive pregnant women who attend
FACES-supported sites. For each study participant, data were
abstracted from the FACES database until her infant was
approximately six months old (12 months after study enrollment).
In addition, study registers were used to monitor study recruit-
ment, enrollment in HIV care, infant HIV testing uptake and
results, and for follow-up of women who do not return to the
health facility for a return visit.
Regardless of study facility or arm, mothers were encouraged to
bring their infants to the clinic for HIV testing at 6 weeks of age
and 6 weeks after the cessation of breastfeeding. In the initial study
period, if a woman had not brought in her child for testing by the
time the child was 7 months old, a FACES staff member
conducted a home visit to ascertain whether the infant had been
tested or not and to encourage the family to bring the infant in for
testing, and for the mother and other family members to enroll in
HIV care and treatment. Starting in November 2010, FACES
began to support home-based testing services for HIV-exposed
infants at the 12 facilities engaged in the SHAIP trial. FACES staff
were trained to offer dried blood spot (DBS) infant testing during a
home visit for HIV-exposed infants who had not been brought to
the clinic by the age of three months. During these home visits,
mothers are asked for permission to test their infant for HIV at the
home using a heel-stick DBS or are referred to the clinic.
Site assessments of the clinics were performed every six months
to monitor service delivery parameters and various aspects of
service integration, including fidelity to the randomized service
model. These assessments were also used to identify needs for
refresher trainings due to staff turn-over and to make other
changes such as addressing insufficient supply of commodities such
as HIV test kits and condoms.
Monitoring
External monitoring for this study was conducted by FHI 360,
including initial site assessment visits, interim monitoring visits,
and study close-out visits. Internal monitoring such as form
completion and quality control of data entry were conducted on a
monthly basis by the study team. Data collection was completed as
of March 31, 2012 and the database was closed as of June 29,
2012.
Figure 3. Randomization of clinic sites. Twelve facilities were categorized by facility type, as either ‘‘Health Center or Dispensary’’ (N = 8) or
‘‘Hospital’’ (N = 4). Within these strata, each clinic represented a cluster, and was randomized to either control (Non-Integrated) or intervention (Fully
Integrated) using the ACluster software.
doi:10.1371/journal.pone.0044181.g003
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Statistical Methods
Analyses will examine the effects of integration on service
uptake and retention at each step of the PMTCT cascade, as well
as effects on vertical transmission of HIV and maternal health
outcomes. Analyses will mainly be performed at the cluster (health
facility) level and any individual-level analyses will take into
account cluster effects [40]. Primary analyses will be based on the
‘‘intention-to-treat’’ (ITT) principle, with facilities randomized to
the intervention group classified as delivering ‘‘fully integrated
services’’ regardless of whether or not individual women actually
received integrated services. In addition, we will perform an
according-to-protocol (ATP) analysis, taking into consideration the
assessments of integration performed every six months at each site.
Assessment data will be used to compute an ‘‘integration index’’
which takes into account various aspects of the integration of
services including the location and functioning of trained staff,
services, infrastructure, equipment, and supplies. This index will
be used to assess variability in the service delivery models for both
intervention and control clinics.
In this initial paper, we compared participant characteristics
between participants enrolled at intervention (FI) and control (NI)
sites using proportions for categorical variables and means or
medians (as appropriate) for continuous variables. An assessment
of the distribution (normally or skewed) of continuous variables
was performed. Socio-demographic and clinical characteristics of
participants enrolled at intervention and control sites were
compared using methods to account for the similarity (intracluster
correlation) between participants enrolled at each site. Statistical
tests used included chi-square tests for categorical variables and
Student’s t-tests for continuous variables, and were adjusted for
clustering effects using the clttest and clchi2 routines in Stata
version 11 (StataCorp., College Station, TX, USA).
Results
Baseline Characteristics of Participants
Table 2 presents the baseline characteristics of pregnant women
enrolled in the study by study arm. The distributions of the
continuous variables did not deviate significantly from the normal
distribution and thus t-test methods could be used to test the
differences between the two groups. The intervention and control
cohorts were similar at baseline with respect to their mean age, the
patient’s report of whether or not her male partner had been tested
for HIV, patient-reported sero-discordance of the couple, marital
Figure 4. Clinical services provided in the ANC Clinic at Fully Integrated sites and Non-Integrated sites. ANC, PMTCT, and HIV services
available at the Fully Integrated sites and Non-Integrated sites based on Kenyan National guidelines.
doi:10.1371/journal.pone.0044181.g004
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status, education, obstetric history, and baseline CD4 count.
Participants in the intervention group were somewhat more likely
to have WHO stage 3 or 4 disease and less likely to have WHO
stage 1 disease than participants in the control group, although
these differences were not statistically significant. The majority of
participants were relatively young women (median age 25.3 years),
had low educational level (only 13.2% had more than a primary
school education), and were married (84.3%).
Implementation Challenges
Conducting implementation science research in the context of a
dynamic HIV service program has presented both methodological
and logistical challenges. Study initiation was delayed for two years
after initial approval from the funder due to bureaucratic hurdles;
therefore some aspects of the service environment had already
changed between study design and implementation. In addition, it
would have been ideal if all clinic sites would have begun the study
simultaneously. However, at the time of study initiation, not all of
the sites met all of the protocol requirements for site initiation. Due
to a combination of issues listed above, study initiation was
staggered across the 12 sites over a nine-month period. However,
the timing of study initiation was balanced between intervention
and non-intervention clinics. Study clinics, like other clinics in this
region, regularly faced challenges to providing high quality care.
During the course of the study there were periods of staff turnover,
staff shortages, lack of HIV test kits or other critical clinic supplies
and equipment. For some study participants, baseline CD4 counts
and follow-up CD4 counts could not be obtained due to lack of
laboratory supplies and inadequate transportation systems to get
lab specimens to the district laboratories. Several sites experienced
Table 2. Baseline characteristics of study participants (N = 1121)a.
FI (n=549) NI (n=572) All (N=1121) All n Test Statisticb P value
Mean age in years (SE) 25.4 (0.2) 25.2 (0.2) 25.33 (0.2) 1121 t =20.64 0.534
Education, n (%) 1102 Chisq = 0.38 0.537
Nonec or Some Primary 461 (85.5%) 495 (87.9%) 956 (86.8%)
Some Secondary or more 78 (14.5%) 68 (12.1%) 146 (13.2%)
WHO stage, n (%) 1027 Chisq = 5.04d 0.169
WHO Stage 1 317 (63.9%) 430 (81%) 747 (72.7%)
WHO Stage 2 72 (14.5%) 34 (6.4%) 106 (10.3%)
WHO Stage 3 or 4e 29 (5.9%) 7 (1.3%) 36 (3.5%)
Not Staged 78 (15.7%) 60 (11.3%) 138 (13.4%)
Mean Baseline CD4 (SE)f 493.2 (20.7) 523.6 (19.4) 508.2 (14.2) 608 t = 1.07 0.309
Baseline CD4, n (%) 608 Chisq = 1.92 0.165
CD4#350 107 (34.9%) 87 (28.9%) 194 (31.9%)
CD4.350 200 (65.1%) 214 (71.1%) 414 (68.1%)
Marital status, n (%) 1065 Chisq = 0.16 0.923
Married 443 (84.4%) 455 (84.3%) 898 (84.3%)
Single/Separated/Divorced 46 (8.8%) 43 (8.0%) 89 (8.4%)
Widowed 36 (6.9%) 42 (7.8%) 78 (7.3%)
Partner tested for HIV
(woman’s report), n (%)
821 Chisq. = 0.06 0.970
Yes 78 (18.4%) 75 (18.9%) 153 (18.6%)
No 190 (44.7%) 172 (43.4%) 362 (44.1%)
Don’t know 157 (36.9%) 149 (37.6%) 306 (37.3%)
Partner’s HIV Status
(woman’s report), n (%)
471 Chisq = 0.66 0.718
HIV Positive 38 (15.6%) 41 (18%) 79 (16.8%)
HIV Negative 29 (11.9%) 17 (7.5%) 46 (9.8%)
Don’t know 176 (72.4%) 170 (74.6%) 346 (73.5%)
Mean No. Pregnancies (SE) 3.1 (0.1) 3.1 (0.1) 3.1 (0.1) 1081 t = 0.09 0.930
Mean Gestational Age at ANC
Visit (weeks) (SE)
25.9 (0.3) 25.3 (0.3) 25.6 (0.2) 1066 t =21.38 0.197
Full Integration (FI), Non Integration (NI), Antenatal care (ANC).
aIndividual variables have n’s less than the overall N due to missing values or non-applicable cases.
bStatistical tests (Chi Square & T-test) were adjusted for clustering using the clttest and clchi2 routines in Stata.
(StataCorp., College Station, TX, USA).
cLess than 1% of the participants had no education.
dIf we exclude those women who were not staged, Chisq = 4.90, p = .086.
eLess than 1% of the participants were at WHO stage 4.
fBaseline CD4 counts were extracted from the study register; however, baseline CD4 counts were not obtained from all participants. Baseline CD4 counts were available
for 307 FI clients and 301 NI clients. All other data were extracted from the participant’s electronic medical record.
doi:10.1371/journal.pone.0044181.t002
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complete staff turnover up to three times during a two-year period
and nearly all sites experienced more than 40% staff turnover
during the study period. Special challenges arose in a few cases
when a staff member from a control site was re-assigned to an
intervention clinic and vice versa. This type of challenge is
inherent in ‘‘real world’’ implementation trials where patient care
must be balanced with the study protocol [41].
The diversity of the study sites, which are dispersed over a wide
geographical area, posed an additional challenge. For example,
one site sits on the banks of Lake Victoria and the population
engages in fishing-related activities that involve extensive travel,
making ongoing follow-up of clients difficult. Other sites serve
predominately farming communities, which tend to be more
stable. Many sites serve mostly patients from the Luo ethnic group,
while others serve patients from a variety of ethnic groups.
However, the variations in study site and populations increase
external validity and wide applicability.
Recruitment of HIV-positive pregnant women who were not
enrolled in HIV care into the study was slower than expected. This
was partially due to the fact that decentralization and scale up of
HIV care and treatment services in the districts during the study
period led to lower than anticipated numbers of eligible pregnant
women (not already enrolled in HIV care and treatment) at the
study sites. Additionally, HIV prevalence among pregnant women
was lower than expected; 19% of ANC attendees at all FACES-
supported health facilities in Nyanza Province tested HIV-positive
in 2010, in comparison to the 25% prevalence anticipated at the
time the study protocol was written [42]. Thus, study enrollment
took 21 months, instead of the expected 12 months.
In order to improve early uptake of HIV exposed infant
testing, during the study period the sites began conducting home
visits for women who have not returned to the health facility of
ANC care with their infant by 3 months of age, instead of 7
months of age as indicated in the original study protocol. At the
same time, these visits were modified to include home-based HIV
infant testing, whereas in the earlier period women were referred
to the nearest health facility for infant testing. We anticipate that
both of these changes will increase uptake of early infant
diagnosis at both FI and NI sites, and these changes will be
factored into the analyses.
Discussion
The SHAIP Trial will provide important data about the effects
of the full integration of ANC, PMTCT, and HIV care and
treatment services on maternal and infant health outcomes. Many
other models of integration exist–in other contexts the term
‘‘integration’’ has referred to a variety of other service combina-
tions such as: adding PMTCT services to existing ANC services,
integrating HIV care into general primary care, and having HIV
care providers attend ANC clinics on specific days [18,26,43]. We
chose to investigate the effects of fully integrated HIV care and
treatment into ANC clinics because experience in sub-Saharan
Africa suggests that this model might result in the most improved
uptake of HIV care and treatment services by pregnant women
and better outcomes for women and infants [14,15,43]. In
Zambia, for example, researchers conducted a stepped wedge
evaluation and found that integration of ANC and HIV services
doubled the proportion of treatment-eligible women enrolling in
HIV care, as well as doubling the proportion of treatment-eligible
women initiating HAART while pregnant [12]. In South Africa,
researchers conducted a pre-post evaluation and found that
strengthening linkages and integrating key components of ARV
treatment within antenatal care significantly reduced the time to
treatment initiation [43].
This study will contribute to the growing body of research on
integration of HIV services into other primary health care
services globally [12,17,27,44,45]. Although recent systematic
reviews of sexual and reproductive health and HIV integration
intervention studies have found that integration is feasible and
that the majority of studies report positive effects on outcomes
[28,29]; they also point out the dearth of rigorous study designs
examining this issue [28,46]. The SHAIP Trial is the first cluster-
randomized trial of ANC and HIV care service integration in
sub-Saharan Africa.
Sub-studies have been conducted during the course of the
SHAIP Trial to examine potential downsides of ANC and HIV
service integration from the perspectives of patients and providers.
A study of patient satisfaction at 5 fully integrated and 4 non-
integrated sites found that integration resulted in significantly
higher satisfaction with the ANC visit for HIV-positive women,
without adversely affecting satisfaction for HIV-negative women
[47]. Interviews with healthcare providers at SHAIP sites
indicated that most providers were supportive of integration and
expected positive effects for their clients, but were concerned about
effects on workload, disclosure, and the quality of care [48].
The implementation challenges presented above introduce
some limitations to the study. Insufficient staffing and supplies at
the study facilities at some time periods during the course of the
study may mean that the full benefits of services could not always
be realized for all women enrolled in the study, thus potentially
diluting the effects of service integration. Lack of adequate systems
for obtaining baseline and follow-up CD4 counts for pregnant
women at the study health facilities may result in inadequate
power to examine differences in the maternal health outcome of
change in CD4 counts. The relatively small number of sites (12)
and their diversity mean that there may be imbalances in the two
study arms that may not be captured by available variables. The
longer than expected enrollment period for the study means that
the analyses will need to take into account changes in national
guidelines and program practices during the study period, which
will make the analyses and their interpretation more complex.
Although demonstration of cost-effectiveness was not included
in the design of this trial, there are indications that the integration
model tested may be cost-effective. This model of service
integration did not involve adding any additional staff or resources
beyond the normal MoH and FACES inputs to these health
facilities. Effective operation of both service delivery models
(integrated or non-integrated) requires healthcare provider train-
ing and ongoing mentorship. The Kenyan MoH has already
stated a commitment to integration of HIV and Reproductive
Health services and is ready to scale up integration if beneficial
effects on health service utilization and outcomes are demonstrat-
ed [49].
In addition to the primary results on the effects on health service
uptake and health outcomes, this study will include detailed
analysis to help understand factors related to successful integration
and improvement of ANC, PMTCT and HIV care; such as
patient load, facility size, and staff composition. Furthermore,
patient characteristics such as age, marital status, and HIV
disclosure will be analyzed to elucidate which patients are most
influenced by integration. A concurrent study on HIV/AIDS
stigma conducted at some of the SHAIP sites [50] will also allow us
to examine potential effects of service integration on pregnant
women’s fears and experiences of HIV/AIDS stigma in this
setting. Overall, the SHAIP study will provide much-needed, high-
quality evidence about the popular concept of integration.
Study of HIV and Antenatal Care Integration
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